COVID-19 Drug Study for Out-Patient Care

Phase 2/3 of RHB-107 (Upamostat), a Serine Protease Inhibitor or Placebo for Treatment of COVID-19 Disease

Upamostat, a Serine Protease Inhibitor or Placebo for Treatment of COVID-19 Disease
AGE: > 18 years old
TYPE: Experimental Treatment Study
CONDITION: COVID-19, Coronavirus
COMPENSATION: Compensation and parking vouchers may be provided.

Learn More About This Research Study

Please call 1-833-788-7425 for more information or complete the online form below.

Purpose of the Study

The purpose of this study is to test the safety of the study drug RHB-107, also referred to as Upamostat, in two different doses to see if it can help people with early COVID-19. Participants in this study will receive either a high or low dosage of Upamostat and/or placebo and will take it by mouth once per day for 14 days.

Who Can Participate

Enrollment is competitive, and researchers hope to enroll a total of 310 participants in several U.S. sites.

Participants must be 18 years or older, started having symptoms or had a positive test for COVID-19 disease within five days from the planned start of study treatment, do not require hospitalization, and can use a smartphone may be eligible for the study. Eligible participants will take the study drug or placebo in a capsule by mouth once a day for up to 14 days. This study only has one in-person clinic visit; then, participants will be monitored closely for the study’s duration, up to 57 days, through phone apps, telehealth, and home health care visits.

Request More Information

To learn more about this study, please fill out the form below to request more information.



Study ID